Advancing diagnostic and vaccine development with virus-like particles

Virus-like particles (VLPs) are non-infectious structures that mimic key structural and antigenic characteristics of native viruses while lacking the genetic material required for replication. Their ability to present viral antigens in a biologically relevant format makes them valuable tools for diagnostic assay development, vaccine research and infectious disease studies. LGC's portfolio includes VLPs, antibodies, antigens and recombinant proteins that support a broad range of research and development applications.

Virus-like particles for vaccine development and infectious disease research

Virus-like particles form part of LGC's infectious disease reagent portfolio and support vaccine, diagnostic and therapeutic development programmes. By mimicking native viral structures, VLPs provide researchers with biologically relevant materials for investigating immune responses, evaluating antigen presentation and supporting the development of infectious disease assays.

Applications include:

• Vaccine research
• Diagnostic assay development
• Infectious disease studies

Custom protein development for emerging infectious disease applications

LGC provides custom protein development services to support emerging infectious disease programmes, novel assay development projects and specialised research requirements. Custom development projects are tailored to specific technical objectives and can help researchers access reagents aligned to unique assay targets and development goals.

Potential project areas include:

• Custom antigen development
• Emerging infectious disease targets
• Diagnostic assay development
• Vaccine research programmes
• Assay-specific reagent development